City

Clinical trials near Baton Rouge, United States

Active studies with a listed research site in Baton Rouge, United States.

39active studies

21recruiting now

22countries represented

140largest site network

Current studies

Status and location data reflect the registry snapshot built 2026-09-08. Verify the original record before contacting a site.

Recruiting nowPhase 3

Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)

Obesity, OverweightCondition

Maridebart cafraglutide, PlaceboTreatment

Australia, Japan87 locations

AmgenSponsor

Updated 2026-09-03 · NCT07684235See eligibility →

Recruiting nowPhase 3

Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)

Obesity or OverweightCondition

Maridebart CafraglutideTreatment

Puerto Rico, United States45 locations

AmgenSponsor

Updated 2026-08-27 · NCT07575399See eligibility →

Recruiting nowPhase 4

GLP-1R Actions on Muscle and the Skeleton

Musculoskeletal Abnormalities, ObesityCondition

Tirzepatide, Lifestyle toolkitTreatment

United States2 locations

Pennington Biomedical Research CenterSponsor

Updated 2026-08-27 · NCT07154719See eligibility →

Recruiting nowNot applicable

Collaborative Multi-level Obesity Intervention Engaging Communities Trial

ObesityCondition

Health Literacy and Culturally Tailored Materials, Community-Engaged Health Coaching and NavigationTreatment

United States18 locations

Tulane UniversitySponsor

Updated 2026-08-11 · NCT06835686See eligibility →

Recruiting nowPhase 3

Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)

Obesity, OverweightCondition

Aleniglipron, PlaceboTreatment

United States71 locations

Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure TherapeuticsSponsor

Updated 2026-08-10 · NCT07654361See eligibility →

Recruiting nowPhase 2

Phentermine's Impact on Treatment in Teens

Childhood ObesityCondition

Phentermine, PlaceboTreatment

United States6 locations

Russell McCulloh, MDSponsor

Updated 2026-08-10 · NCT07282340See eligibility →

Recruiting nowNot applicable

Low Oxygen Exposure and Weight Status

ObesityCondition

Normobaric hypoxia (NH), Normobaric normoxia (NN)Treatment

United States1 locations

Pennington Biomedical Research CenterSponsor

Updated 2026-07-16 · NCT05289310See eligibility →

Recruiting nowNot applicable

Body Composition Outcomes in MS Patients

ObesityCondition

Intervention not listedTreatment

United States2 locations

Pennington Biomedical Research CenterSponsor

Updated 2026-06-17 · NCT07530718See eligibility →

Recruiting nowNot applicable

Experimental Approach to Test Predictions of Body Weight Regulation Models

Obesity, UnderweightCondition

Fasting-refeeding cycleTreatment

United States1 locations

Pennington Biomedical Research CenterSponsor

Updated 2026-05-29 · NCT06309576See eligibility →

Recruiting nowNot applicable

Iron Absorption in The Low Oxygen Exposure and Weight Status (LOWS) Study

Obesity (Disorder)Condition

Normobaric hypoxia (NH), Normobaric normoxia (NN)Treatment

United States1 locations

Pennington Biomedical Research CenterSponsor

Updated 2026-04-21 · NCT07542873See eligibility →

Recruiting nowNot applicable

Testing the Adipose Expandability Hypothesis In Vivo During Overfeeding

Overweight and Obesity, Metabolic SyndromeCondition

Control, OverfeedingTreatment

United States1 locations

Pennington Biomedical Research CenterSponsor

Updated 2026-04-08 · NCT04583514See eligibility →

Recruiting nowNot applicable

Assessments of Adipogenesis, Lipid Turnover and Cellular Composition in Adipose Tissue in Response to Endurance Exercise

ObesityCondition

Muscle Biopsy, Adipose BiopsyTreatment

United States2 locations

AdventHealth Translational Research InstituteSponsor

Updated 2026-03-27 · NCT06602141See eligibility →

Recruiting nowNot applicable

Impact of Lean Pork on Endothelial Function in Perimenopause

Cardiovascular Outcome, Overweight and Obese WomenCondition

Pork Diet, Plant DietTreatment

United States1 locations

Pennington Biomedical Research CenterSponsor

Updated 2025-11-28 · NCT06976112See eligibility →

Recruiting nowPhase 1

A Study to See How Metabolism is Influenced by Weight Loss Due to Intervention With Cagrilintide and Semaglutide Compared to Diet

ObesityCondition

CagriSema (Cagrilintide B + semaglutide I), Low Energy DietTreatment

United States2 locations

Novo Nordisk A/SSponsor

Updated 2025-10-08 · NCT07184086See eligibility →

Recruiting nowNot applicable

The Dose Trial: Dose Intensity of Behavioral Interventions for Childhood Obesity

Childhood ObesityCondition

Intensive Behavioral Lifestyle ModificationTreatment

United States2 locations

Vanderbilt University Medical CenterSponsor

Updated 2025-09-08 · NCT06654323See eligibility →

Recruiting nowNot applicable

Studying Phenotypic Risks for Obesity and Underlying Traits in Young Infants

Infant Body Composition and Metabolism, MetabolismCondition

Meal Test - Human Milk, Meal Test - Infant FormulaTreatment

United States1 locations

Pennington Biomedical Research CenterSponsor

Updated 2025-08-22 · NCT07096011See eligibility →

Recruiting nowNot applicable

Assessing the Value of Avocados on Glycemic Control in Type 2 Diabetes

Diabetes Mellitus, Type 2, InsulinCondition

Avocado, Other Fruit(s)Treatment

United States1 locations

Pennington Biomedical Research CenterSponsor

Updated 2025-07-31 · NCT05958368See eligibility →

Recruiting nowNot applicable

Pennington Generation Cohort

Obesity PreventionCondition

Intervention not listedTreatment

United States1 locations

Pennington Biomedical Research CenterSponsor

Updated 2025-03-17 · NCT06849206See eligibility →

Recruiting nowPhase 4

Treatment to Regress to Normoglycemia in Women with a Recent History of GDM

Pre Diabetes, Postpartum DisorderCondition

Semaglutide Pen Injector [Ozempic], Placebo semaglutide pen injectorTreatment

United States1 locations

Woman'sSponsor

Updated 2025-03-13 · NCT04873050See eligibility →

Recruiting nowNot applicable

The Effects of Metabolic & Bariatric Surgery on Lipid Metabolism, Myeloid-Derived Suppressor Cells, and Cancer Cell Biology

ObesityCondition

Metabolic & Bariatric SurgeryTreatment

United States1 locations

Pennington Biomedical Research CenterSponsor

Updated 2025-02-17 · NCT06059651See eligibility →

Recruiting nowNot applicable

International Weight Control Registry

Weight Loss, OverweightCondition

Intervention not listedTreatment

United States7 locations

Tufts UniversitySponsor

Updated 2024-09-19 · NCT04907396See eligibility →

Opening soonNot applicable

Ability of Almonds to Improve Nutrition During GLP-1 Treatment

Obesity, Type 2 DiabetesCondition

Almond DietTreatment

United States1 locations

Pennington Biomedical Research CenterSponsor

Updated 2026-09-01 · NCT07796204See eligibility →

Opening soonNot applicable

Digital Resistance Training for Midlife Women Using GLP-1

Women's Health, Obesity & OverweightCondition

PLAN-RT 1.0Treatment

United States1 locations

Louisiana State University and A&M CollegeSponsor

Updated 2026-08-26 · NCT07787533See eligibility →

Opening soonNot applicable

Continuous Glucose Monitoring in Metabolic Surgery

Obesity (Disorder)Condition

Abbot Freestyle Libre CGMTreatment

United States1 locations

Pennington Biomedical Research CenterSponsor

Updated 2026-07-09 · NCT07095972See eligibility →

Active, not recruitingPhase 2

Proof-of-Concept Study Evaluating Total Body Weight, Physical Function & Safety of Enobosarm in Patients Treated With GLP-1 Receptor Agonist, for Weight Loss

Obesity & Overweight, Mobility DisabilityCondition

Enobosarm, Semaglutide (Wegovy) weekly injectionTreatment

United States13 locations

Veru Inc.Sponsor

Updated 2026-09-04 · NCT07446998See eligibility →

Active, not recruitingPhase 3

A Research Study on How Well Semaglutide Helps Children and Teenagers With Excess Body Weight Lose Weight

ObesityCondition

Semaglutide, PlaceboTreatment

Austria, Belgium56 locations

Novo Nordisk A/SSponsor

Updated 2026-08-07 · NCT05726227See eligibility →

Active, not recruitingPhase 3

A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity

ObesityCondition

Retatrutide, TirzepatideTreatment

Argentina, Germany65 locations

Eli Lilly and CompanySponsor

Updated 2026-07-20 · NCT06662383See eligibility →

Active, not recruitingPhase 3

SCALE KIDS: Research Study to Look at How Well a New Medicine is at Lowering Weight in Children With Obesity

ObesityCondition

Liraglutide, PlaceboTreatment

Belgium, India32 locations

Novo Nordisk A/SSponsor

Updated 2026-07-09 · NCT04775082See eligibility →

Active, not recruitingPhase 3

A Study of Tirzepatide (LY3298176) Once Weekly in Adolescent Participants Who Have Obesity or Overweight With Weight-Related Comorbidities

Obesity, OverweightCondition

Tirzepatide, PlaceboTreatment

Canada, Czechia33 locations

Eli Lilly and CompanySponsor

Updated 2026-06-29 · NCT06075667See eligibility →

Active, not recruitingNot applicable

Ultra-processed Food Consumption and Health Pilot Study

Obesity & OverweightCondition

Purple Diet, Ultra-processed dietTreatment

United States1 locations

Pennington Biomedical Research CenterSponsor

Updated 2026-06-29 · NCT07318064See eligibility →

Active, not recruitingPhase 1

A Study to Test Whether Survodutide Improves How the Body Uses Energy and Breaks Down Fat in People With Obesity

ObesityCondition

Survodutide, SemaglutideTreatment

United States2 locations

Boehringer IngelheimSponsor

Updated 2026-05-12 · NCT06745284See eligibility →

Active, not recruitingPhase 3

VK2735 for Weight Management Type 2 Diabetes Phase 3 (VANQUISH 2)

Weight LossCondition

VK2735Treatment

Puerto Rico, United States127 locations

Viking Therapeutics, Inc.Sponsor

Updated 2026-04-07 · NCT07104383See eligibility →

Active, not recruitingPhase 4

Effect of Naltrexone Hydrochloride ER and Bupropion Hydrochloride ER Combination (Contrave®/Mysimba®) on Major Adverse Cardiovascular Events (MACE)

ObesityCondition

Naltrexone-Bupropion (NB) Combination, PlaceboTreatment

United States140 locations

Currax PharmaceuticalsSponsor

Updated 2026-03-31 · NCT06098079See eligibility →

Active, not recruitingPhase 2

Taldefgrobep Alfa in Adults With Overweight and Obesity

Obesity, OverweightCondition

Taldefgrobep Alfa, PlaceboTreatment

United States20 locations

Biohaven Therapeutics Ltd.Sponsor

Updated 2026-03-20 · NCT07281495See eligibility →

Active, not recruitingPhase 3

A Study of Retatrutide (LY3437943) in the Maintenance of Weight Reduction in Individuals With Obesity

ObesityCondition

Retatrutide, PlaceboTreatment

Canada, United Kingdom53 locations

Eli Lilly and CompanySponsor

Updated 2026-03-03 · NCT06859268See eligibility →

Active, not recruitingPhase 3

VK2735 for Weight Management Phase 3

Weight LossCondition

VK2735Treatment

Puerto Rico, United States137 locations

Viking Therapeutics, Inc.Sponsor

Updated 2025-11-24 · NCT07104500See eligibility →

Active, not recruitingNot applicable

Dietary, Physiological, Genetic, and Behavioral Predictors of Health in a Young, Ethnically-Mixed Population

ObesityCondition

Intervention not listedTreatment

United States1 locations

Pennington Biomedical Research CenterSponsor

Updated 2025-08-22 · NCT00945633See eligibility →

Active, not recruitingNot applicable

Promoting Successful Weight Loss in Primary Care in Louisiana Using Information Technology

Obesity, Diabetes Mellitus, Type 2Condition

Intensive Lifestyle InterventionTreatment

United States1 locations

Pennington Biomedical Research CenterSponsor

Updated 2025-03-17 · NCT05523375See eligibility →

Active, not recruitingNot applicable

TARGETing Healthy Weight Loss in the Context of Food Insecurity

Obesity, Food InsecurityCondition

Intervention not listedTreatment

United States1 locations

Pennington Biomedical Research CenterSponsor

Updated 2025-02-04 · NCT05601804See eligibility →

How current is this page?

The page is rebuilt from the public registry feed. Each trial card shows the registry update date. Recruitment can still change between builds.

Does appearing here mean I qualify?

No. These pages are discovery indexes. Only a study team can confirm eligibility after reviewing the complete protocol criteria.

Clinical trials near Baton Rouge, United States

Current studies

Related cities